Stocktoria
Eton Pharmaceuticals, Inc. ETON
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-11-09
Eton Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M | $39,000 | $959,000 | — |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.0M | -$397,000 | $506,000 | — |
| R&D expense | $7.8M | $3.3M | $3.3M | $4.0M | $6.2M | $14.1M | $11.6M | $5.6M |
| Operating income | -$844,000 | -$2.6M | -$1.2M | -$8.3M | -$1.5M | -$27.1M | -$18.6M | -$10.3M |
| Interest expense | — | — | $1.1M | $955,000 | $1.0M | $884,000 | $98,000 | — |
| Income tax | $43,000 | $15,000 | $247,000 | $0 | $0 | — | — | — |
| Net income | -$4.6M | -$3.8M | -$936,000 | -$9.0M | -$2.0M | -$28.0M | -$18.3M | -$12.7M |
| Operating cash flow | $10.5M | $969,000 | $6.8M | $4.8M | -$4.7M | -$22.3M | -$18.0M | -$8.1M |
| Free cash flow | $10.2M | $943,000 | $6.8M | $4.8M | -$4.7M | -$22.4M | -$19.1M | -$8.4M |
| Cash & equivalents | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M | $21.3M | $12.1M | $26.7M |
| Inventory | $15.4M | $15.2M | $911,000 | $557,000 | $550,000 | $1.2M | $380,000 | — |
| Total assets | $92.1M | $76.1M | $31.7M | $25.0M | $27.5M | $26.3M | $17.1M | $28.3M |
| Total liabilities | $66.0M | $51.7M | $16.3M | $12.0M | $9.8M | $10.7M | $6.5M | $2.0M |
| Shareholders' equity | $26.2M | $24.4M | $15.5M | $13.1M | $17.6M | $17.6M | $10.6M | $26.3M |
Growth · year-over-year · Revenue CAGR 109%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +104.9% | +23.3% | +48.9% | -2.7% | +55879.5% | -95.9% | — | — |
| Free cash flow growth | +980.7% | -86.2% | +42.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.